Tesaro Raises Capital For Oncology Portfolio | Chemical & Engineering News
Volume 89 Issue 26 | p. 17 | Concentrates
Issue Date: June 27, 2011

Tesaro Raises Capital For Oncology Portfolio

Department: Business
Keywords: financing, drug development, pharmaceuticals

Tesaro has raised $101 million from venture capital investors. The Waltham, Mass.-based biotech firm was founded in May 2010 by former executives of MGI Pharma, which Japan’s Eisai acquired in 2008 for $3.9 billion. Tesaro has licensed the neurokinin-1 receptor antagonist rolapitant from OPKO Health and small-molecule inhibitors of anaplastic lymphoma kinase from Amgen. Among other things, the money will support Phase III trials of rolapitant, a candidate to prevent chemotherapy-induced nausea and vomiting.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment